已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta‐analysis‐based comparison of treatment efficacy

医学 荟萃分析 置信区间 掌跖脓疱病 随机对照试验 优势比 梅德林 分级(工程) 系统回顾 随机效应模型 内科学 物理疗法 皮肤病科 银屑病 工程类 土木工程 政治学 法学
作者
Takemichi Fukasawa,Takashi Yamashita,Atsushi Enomoto,Asako Yoshizaki‐Ogawa,Kiyoshi Miyagawa,Shinichi Sato,Ayumi Yoshizaki
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:38 (2): 281-288 被引量:5
标识
DOI:10.1111/jdv.19499
摘要

Few studies have made direct comparisons between treatments for palmoplantar pustulosis (PPP); therefore, it is difficult to select the best treatment for each patient. To determine the best therapy and to compare reported measures of efficacy in clinical trials of systemic treatments for PPP in this systematic review and network meta-analysis. Six databases were used to perform database search on 10 July 2022. Randomized controlled trials (RCTs) were identified through a systematic literature search. The titles and abstracts of articles were initially screened for inclusion by two authors independently using our predetermined criteria. The full texts of selected articles were then independently assessed for inclusion in a blinded fashion. Disagreement between the authors was resolved by consensus. Data were abstracted in duplicate. Random-effects model was accepted to perform network meta-analysis. Assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed according to the PRISMA guidelines. The analysis was completed in July 2022. The primary outcome was the change of PPP Area and Severity Index (PPPASI) from baseline and the secondary outcome was the achievement of PPPASI-50 response. Seven RCTs with 567 patients were included. Guselkumab 100 mg was the one with the highest probability of reaching the proposed outcomes (mean difference [MD], -8.00; 95% confidence interval [CI], 4.88-11.11), while the achievement of PPPASI-50 response did not show a significant difference (odds ratio [OR], 3.79; 95% CI, 0.51-28.37). Guselkumab 200 mg was next to 100 mg of reaching the proposed outcomes (MD, -4.71; 95% CI, 2.12-7.30), while the achievement of PPPASI-50 response did not show a significant difference (OR, 2.34; 95% CI, 0.48-11.43). Network meta-analysis showed guselkumab 100 mg was the treatment with the highest probability of reaching both PPPASI and PPPASI-50 outcomes. Absolute PPPASI may be more appropriate as an outcome than PPPASI-50.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
大春发布了新的文献求助10
2秒前
4秒前
南风不竞发布了新的文献求助10
4秒前
4秒前
ZYN完成签到,获得积分10
6秒前
盒子发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
7秒前
LJP发布了新的文献求助10
8秒前
王诗翔完成签到,获得积分10
8秒前
迅速罡发布了新的文献求助10
9秒前
qqqq发布了新的文献求助10
11秒前
11秒前
afanda发布了新的文献求助10
12秒前
我想长高完成签到,获得积分10
13秒前
猫小乐C发布了新的文献求助20
14秒前
虚心的绝施完成签到 ,获得积分10
14秒前
bkagyin应助向日葵的微笑采纳,获得10
16秒前
17秒前
18秒前
酷酷的硬币完成签到,获得积分10
18秒前
郭敏菲完成签到,获得积分10
19秒前
迅速罡完成签到,获得积分10
19秒前
晶晶完成签到 ,获得积分10
19秒前
祝余完成签到,获得积分20
21秒前
雪白萤完成签到 ,获得积分10
21秒前
卡拉米发布了新的文献求助10
22秒前
郭敏菲发布了新的文献求助10
23秒前
英俊的铭应助犹豫夜白采纳,获得10
23秒前
夏飞飞完成签到,获得积分10
23秒前
情怀应助科研通管家采纳,获得10
24秒前
李健应助科研通管家采纳,获得10
24秒前
lysenko完成签到 ,获得积分10
24秒前
Ryan应助lulu采纳,获得10
25秒前
领导范儿应助科研通管家采纳,获得10
25秒前
科研通AI6.1应助11011采纳,获得10
25秒前
所所应助科研通管家采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
Elgar Concise Encyclopedia of Space Law 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6944437
求助须知:如何正确求助?哪些是违规求助? 8629885
关于积分的说明 18305557
捐赠科研通 6379654
什么是DOI,文献DOI怎么找? 3079291
关于科研通互助平台的介绍 2120203
邀请新用户注册赠送积分活动 2056180